Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx) -- Ignore unavailable to you. Want to Upgrade?

To: ggamer who wrote (371)	2/26/2008 1:15:26 PM
From: Keith Feral	Read Replies (2) \| Respond to of 418

I have no problems rolling the dice at cash value. It all comes down to Vinorelbine and Docetaxel. Docetaxel is a much bigger market than Leucovorin. Still, Cofactor has some chance for success. $0.50 is a great price for the shares to go back to their prior levels. If the Chief Medical Officer from Imclone is willing to join the Board, I think it's worth my time to give them another shot. It's pure speculation again, with all of the downside risks already built into the value of the company.